Notice: Wiley Online Library will be unavailable on Saturday 30th July 2016 from 08:00-11:00 BST / 03:00-06:00 EST / 15:00-18:00 SGT for essential maintenance. Apologies for the inconvenience.
Potential conflict of interest: Nothing to report.
Supported by National Institutes of Health grants CA106280, CA102325, CA134568, and DK077776 (to T.W.).
Address reprint requests to: Tong Wu, M.D., Ph.D., Department of Pathology and Laboratory Medicine, Tulane University School of Medicine, 1430 Tulane Ave., SL-79, New Orleans, LA 70112. E-mail: email@example.com; fax: 504-988-7862.
Hedgehog (Hh) signaling plays an important role in embryonic development and in the regulation of a variety of cellular functions. Aberrant activation of Hh signaling has been implicated in several human cancers including hepatocellular carcinoma (HCC). In this study we examined the pathobiological functions and molecular mechanisms of the Hh signaling pathway in HCC cells. Treatment of cultured human HCC cells (Huh7, Hep3B, and HepG2) with the Hh signaling ligand (recombinant Shh) or agonist, SAG and purmorphamine, prevented the induction of autophagy. In contrast, GANT61 (a small molecule inhibitor of Gli1 and Gli2) induced autophagy, as determined by immunoblotting for microtubule-associated protein light chain 3 (LC3) and p62, GFP-LC3 puncta, monodansylcadaverine (MDC) staining, and transmission electron microscopy. Hh inhibition-induced autophagy was associated with up-regulation of Bnip3, as determined by immunoblotting and real-time polymerase chain reaction (PCR) assay. Knockdown of Bnip3 by RNAi impaired GANT61-induced autophagy. Additionally, Hh inhibition-induced autophagy was associated with Bnip3-mediated displacement of Bcl-2 from Beclin-1, as determined by immunoblotting and immunoprecipitation assays. Furthermore, inhibition of Hh signaling increased HCC cell apoptosis and decreased cell viability, as determined by caspase and WST-1 assays. Pharmacological or genetic inhibition of autophagy by 3-methyladenine (3-MA) or Beclin-1 small interfering RNA (siRNA) partially suppressed GANT61-induced cell apoptosis and cytotoxicity. In a tumor xenograft model using SCID mice inoculated with Huh7 cells, administration of GANT61 inhibited tumor formation and decreased tumor volume; this effect was partially blocked by the autophagy inhibitor, 3-MA. Conclusion: These findings provide novel evidence that Hh inhibition induces autophagy through up-regulation of Bnip3 and that this mechanism contributes to apoptosis. Therefore, the status of autophagy is a key factor that determines the therapeutic response to Hh-targeted therapies. (Hepatology 2013;53:995–1010)
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.
Hedgehog (Hh) was initially discovered nearly 30 years ago as a “segmentpolarity” gene that controls Drosophila embryonic cuticle pattern. Since the discovery of its vertebrate counterparts in the early 1990s, enormous progress has been made in revealing the role of Hh signaling in development and disease as well as the molecular underpinning of the Hh signaling cascade. We now know that Hh signaling plays an important role in embryonic development and in the regulation of a variety of cellular functions including proliferation, survival, stemness, and differentiation. The Hh signaling pathway consists of Hh ligands (Sonic Hh, Indian Hh, and Desert Hh), the 12-span transmembrane protein, Patched (Ptc), as the Hh receptor, the 7-span transmembrane protein, Smoothened (Smo), as the obligatory signal transducer across the plasma membrane, and the 5-zinc finger transcription factor Glis (Gli-1, Gli-2, and Gli-3). Activation of the canonical Hh signaling pathway is initiated by the binding of Hh ligands to their receptor, Ptc, which becomes internalized leading to the activation of Smo by way of release from Ptc-dependent suppression. Smo activates the final arbiter of Hh signaling, the Gli family of transcription factors that regulate Hh target genes expression, including Ptch1 and Gli1. Recently, aberrant activation of Hh signaling has been implicated in several human malignancies including hepatocellular carcinoma (HCC).[4, 5]
HCC is one of the most common malignancies and one of the leading causes of cancer-related mortality. The overall survival of patients with HCC has not significantly improved in the past two decades. Current treatments are only applicable at early stages of tumor development, including surgery and chemotherapy. But a majority of patients has an advanced or unresectable disease at presentation which makes the prognosis of HCC dismal. Conventional systemic chemotherapy options have typically yielded poor outcomes for these patients. Although in recent years several clinical trials have tested the efficacy of agents that selectively target important signaling pathways involved in the control of HCC, no relevant improvement in patient prognosis has been achieved so far. Therefore, it is urgent and practical to identify novel therapeutic strategies for more effective therapy. In this context, it is encouraging that Hh-targeted therapy has emerged as a potential new treatment for Hh-dependent human cancers including HCC.
Autophagy is an evolutionarily conserved process that involves lysosomal degradation of cytoplasmic and cellular organelles, which consists of several steps including sequestration, transport to lysosomes, degradation, and utilization of degradation products. It is characterized by progressive formation of vesicle structures from autophagosomes to autophagolysosomes, orchestrated by autophagy effectors (Atg proteins) and modulators (i.e., class III phosphatidylinositol-3-kinase). The process of autophagosome formation involves two major steps: nucleation and elongation of the isolation membrane. The Atg1/unc-51-like kinase (ULK) complex, the autophagy-specific PI3-kinase complex, and PI3P-effectors and their related proteins are important for the nucleation step, whereas the Atg12- and LC3/Atg8-conjugation systems are important for the elongation step. Studies have demonstrated that autophagy plays a wide variety of physiological and pathophysiological roles. Recent evidence has shown that autophagy is associated with cancer pathogenesis and that pharmacologic manipulation of autophagic pathways may represent a new therapeutic strategy for human cancers. However, to date the role of autophagy in cancer is not clearly defined. Although autophagy is a cancer cell survival mechanism against environmental and cellular stresses, it can be associated with cancer cell death under certain situations. Further, autophagy and apoptosis might be linked to each other and occur simultaneously or sequentially in a cell type-, death stimulus-, and context-dependent manner.
Although Hh signaling is known to inhibit cell apoptosis, it remains unknown whether Hh signaling is able to regulate autophagy. The current study describes a novel role of the Hh signaling pathway for regulation of autophagy in human HCC cells. We show that inhibition of the Hh pathway markedly enhanced autophagy through up-regulation of Bnip3 (a member of BH3-only subset of the Bcl-2 family) that displaces Bcl-2 from its binding partner, Beclin-1, and that this process preludes apoptosis. Our findings suggest that the status of autophagy (autophagic flux) is a key factor that may influence cell response to Hh-targeted therapy.
Materials and Methods
Human HCC cells (Huh7, Hep3B, and HepG2) were treated with the Hh signaling ligand, agonists, or inhibitors as indicated and the cells were analyzed for autophagy by immunoblotting for microtubule-associated protein light chain 3 (LC3) and p62, GFP-LC3 puncta, monodansylcadaverine (MDC) staining, and transmission electron microscopy (TEM). Western blotting analysis was performed to determine the alteration of key signaling molecules including Shh, Patched, Smo, and Gli1, Bnip3, Bcl-2 family proteins, and MEK/ERK1/2. The interaction between Bcl-2 and Beclin-1 was analyzed by immunoprecipitation and immunoblotting assays.
For quantitative reverse-transcription polymerase chain reaction (qRT-PCR), total RNA was extracted with the TRIzol plus RNA purification kit and reverse-transcribed to complementary DNA (cDNA) using Superscript II reverse transcriptase; the cDNA samples were used for real-time PCR analysis in triplicate using the QuantiFast SYBR Green PCR kit (Qiagen) on a Bio-Rad C1000 Thermal Cycler.
For plasmid or small interfering RNA (siRNA) transfection, the Bcl-2 and Bnip3 expression plasmid or Bnip3 siRNA were transfected into Huh7 cells by using Lipofectamine 2000; 6 hours posttransfection the cells were treated with the indicated reagents and analyzed for apoptosis while the cell lysates were obtained for western blotting and immunoprecipitation.
For flow cytometry analysis of apoptosis, the cells were harvested, centrifuged, and resuspended in 100 μL Annexin-V-FLUOS labeling solution containing of 2 μL Annexin-V-FLUOS labeling reagent and 2 μL propidium iodide solution and the cells were analyzed on a FACScan Flow Cytometer (BD LSRII).
A tumor xenograft model was used to evaluate the effect of Hh inhibition on HCC growth in SCID mice. Male SCID mice were subcutaneously inoculated into the flank with 1 × 107 Huh7 cells. One week postinoculation, the mice were randomized to three groups and treated with vehicle only, GANT61 (50 mg/kg), and GANT61 (50 mg/kg) combination with 3-MA (10 mg/kg) by intraperitoneal injection every other day for 4 weeks. The animals were closely observed to document the tumor growth parameters. The tumor tissues were used for hematoxylin and eosin (H&E) staining, western blotting analysis for LC3II and caspases, and immunofluorescent staining for LC3II.
Hh Signaling Pathway Is Active in Human HCC Cells
Western blot analysis showed that canonical Hh signaling pathway components, including the ligand, Shh, and the signaling molecules, Patched, Smo, and Gli1, were expressed in HCC cell lines (Huh7, HepG2 and Hep3B) (Fig. 1A). These observations are consistent with the reported up-regulation of Hh pathway components in HCC cells and tissues.[4, 5] To determine Hh signaling activity in these cells we employed a Gli-dependent luciferase reporter system, in which the cells were transfected with a Gli-dependent luciferase reporter construct, followed by treatment with recombinant Shh (an Hh ligand), SAG (an Hh agonist that acts downstream by directly binding to Smoothened), purmorphamine (an Hh agonist directly targeting Smoothened), GDC-0449 (Smoothened antagonist), or GANT61 (a small molecule inhibitor of Gli1 and Gli2). As shown in Fig. 1B, activation of Hh signaling by its ligand (Shh) and agonists (SAG or Pur) enhanced Gli-dependent luciferase reporter activity, whereas inhibition of Hh signaling by GANT61 and GDC-0449 reduced Gli reporter activity. Accordingly, activation of Hh signaling by Shh, SAG, or Pur in Huh7 cells increased the mRNA levels of two Gli target genes, Ptch1 and Gli1, while inhibition of Hh signaling by GANT61 or GDC-0449 reduced Ptch1 and Gli1 mRNAs (Fig. 1C). The Gli inhibitor GANT61 reduced Gli reporter activity and downstream gene expression to a greater extent than the Smo inhibitor GDC-0449. These findings suggest an autocrine mode of Hh signaling activation in HCC cells.
Inhibition of Hh Signaling Induces Autophagy
To determine the impact of Hh signaling on autophagy, Huh7, HepG2, and Hep3B cells were treated with the Hh pathway agonists or antagonists and the cells were analyzed to determine the level of LC3II, an essential component and a widely used marker for autophagosomes. Western blot analysis showed that treatment with the Gli inhibitor GANT61 induced the accumulation of LC3II in all three HCC cell lines (Fig. 2A). Treatment with the Smo inhibitor GDC-0449 also increased the LC3II level, albeit the effect was less prominent compared to GANT61. In contrast, activation of Hh signaling by its ligand (Shh) and agonists (SAG or Pur) decreased the level of LC3II.
In addition to LC3II western blot, we further used fluorescence microscopy to determine the redistribution of GFP-LC3 (LC3 is a mammalian homolog of yeast Atg8 and is normally expressed in a diffuse pattern in resting cells; during autophagy, autophagosomes engulf bulk cytoplasmic constituents including proteins and organelles, and along this process, the cytosolic form of LC3 [LC3I] is conjugated to phosphatidylethanolamine to form LC3II, which is recruited to autophagosomal membranes resulting in a more punctate distribution pattern). As shown in Fig. 2B, GANT61 treatment induced GFP-LC3 dot redistribution from a diffuse pattern to a punctate cytoplasmic pattern (GFP-LC3 puncta) in all three HCC cell lines. The Smo inhibitor GDC-0449 also induced GFP-LC3 puncta formation, although the effect was slightly less prominent compared to GANT61. These findings indicate that inhibition of Hh signaling induces autophagy and that the Gli inhibitor GANT61 is a potent agent that induces autophagy. Although GANT61-induced autophagy is observed in all three HCC cell lines, the effect is most prominent in Huh7 cells (Fig. 2A).
To further document the effect of GANT61 on autophagy, we performed dose-dependent experiments in Huh7 cells (the cells were treated with GANT61 at 5 μM, 10 μM, or 20 μM concentration for 24 and 48 hours; quantitative assessment for the ratio of LC3II to LC3I was used as the primary indicator of autophagy induction). As shown in Fig. 2C, GANT61-induced LC3II accumulation in a dose-dependent manner.
Increased detection of autophagic markers, such as LC3II accumulation and GFP-LC3 redistribution, can result from either increased autophagosome formation or inhibition of ongoing autophagosomal maturation. To delineate these possibilities, the cells were pretreated with 3-methyladenine (3-MA, a classical inhibitor of autophagy at the sequestration stage) or E-64d/pepstatin A (lysosomal protease inhibitors that block autophagolysosomal degradation) prior to GANT61 treatment. As shown in Fig. 2D, 3-MA treatment abolished GANT61-induced LC3-II formation, whereas E-64d/pepstatin A treatment augmented GANT61-induced LC3-II accumulation. The protein, p62/SQSTM1, binds directly to LC3, incorporates into the completed autophagosomes, and becomes degraded in autolysosomes. In our system we observed that GANT61 treatment decreased the level of p62 in Huh7 cells and the effect was reversed by 3-MA and E-64d/pepstatin A. Taken together, these findings suggest that the Gli inhibitor GANT61 enhanced autophagic flux.
In addition to utilization of LC3II accumulation and GFP-LC3 redistribution as markers of autophagy, we further employed MDC (monodansylcadaverine) staining and TEM to verify induction of autophagy by GANT61. MDC is an autofluorescent agent that is accumulated specifically in autophagolysosomes. As shown in Supporting Fig. S1A, treatment with GANT61 and GDC-0449 induced the accumulation of MDC in the cytoplasmic vacuoles in Huh7 cells (the accumulation was greater in GANT61-treated cells compared to GDC-0449-treated cells). TEM also showed formation of autophagosomes and autophagolysosomes in GANT61-treated Huh7 cells, characterized by double-membrane vacuolar structures containing cytoplasmic contents (Supporting Fig. S1B).
Activation of Hh Signaling Prevents Autophagy
To assess the impact of Hh signaling activation on autophagy, HCC cells were treated with autophagy-inducing drugs (carbamazepine and oxaliplatin) in the presence or absence of Hh ligand (Shh) or agonists (SAG or Pur) (carbamazepine is an autophagy-enhancing drug for hepatocytes; oxaliplatin is a second-generation potent platinum-based antineoplastic agent that can induce autophagy in HCC cells). As shown in Fig. 3A,B, activation of Hh signaling by Shh, SAG, or Pur prevented carbamazepine and oxaliplatin-induced LC3II accumulation in all three HCC cells; these findings indicate that activation of Hh signaling is able to prevent autophagy in HCC cells. In contrast, inhibition of Hh pathway by GDC0449 or GANT61 enhanced carbamazepine and oxaliplatin-induced LC3II accumulation in all three HCC cells, which suggest that inhibition of Hh signaling synergizes with autophagy-inducing drugs in autophagy induction (Fig. 3C,D).
GANT61 Does Not Increase ATG Gene Expression
ATG (autophagy-related) genes encode proteins required for autophagy and play essential roles in autophagy. Autophagosome formation is mediated by two ubiquitin-like conjugation systems composed of Atg proteins, which culminate in conjugation of Atg12 to Atg5 and conversion of a soluble form of LC3-I to phosphatidylethanolamine-conjugated membrane-bound form (LC3-II). The proteins Atg3, Atg5, Atg6/Beclin1, Atg7, and Atg12 are involved in autophagosome formation and are well conserved from yeast to humans. Because many autophagic triggers up-regulate ATG genes, we examined whether GANT61 treatment might influence the expression levels of ATG genes in HCC cells. As shown in Supporting Fig. S2, GANT61 treatment did not increase the expression of ATG genes (Atg3 levels was slightly decreased in GANT61-treated Huh7 and Hep3B cells compared to cells treated with vehicle or Hh ligand/agonists). These results suggest that GANT61-induced autophagy is not associated with up-regulation of ATG gene expression.
Bnip3 Mediates GANT61-Induced Autophagy
Although Bcl-2 family proteins were initially characterized as cell apoptosis regulators, it has recently become clear that they also control autophagy, playing a dual role in the regulation of apoptosis and autophagy. Thus, we assessed whether GANT61-induced autophagy might be associated with one or more Bcl-2 family proteins. As shown in Fig. 4A, we observed robust up-regulation of the BH3-only protein, Bnip3, by GANT61 in all three HCC cell lines; the expression of other Bcl-2 family proteins (including Bim, Noxa, Puma, Bcl2, and Bclxl) were not significantly affected, although the level of Mcl-1 was slightly reduced in two of the three HCC cell lines. GANT61 induced a 4.39-fold, 2.84-fold, and 1.97-fold increase in Bnip3 mRNA level in Huh7, Hep3B, and HepG2 cells, respectively, as determined by qRT-PCR (Fig. 4B). The effect of GANT61 on Bnip3 expression was dose-dependent (at 24- and 48-hour timepoints) (Fig. 4C). The role of Bnip3 in GANT61-induced autophagy was supported by the observations that siRNA knockdown of Bnip3 prevented GANT61-induced LC3II accumulation (Fig. 4D, left panel) and that overexpression of Bnip3 enhanced GANT61-induced LC3II accumulation (Fig. 4D, right panel) and reversed SAG-induced LC3II reduction (Fig. 4E).
We sought to further investigate the mechanism by which Hh signaling regulates Bnip3. As the Bnip3 promoter does not contain the Gli consensus DNA-binding sequences, it is likely that Hh signaling might regulate Bnip3 through an indirect mechanism. Given that Bnip3 is a downstream target of the MEK/ERK signaling pathway[11, 12] and that Hh and MEK/ERK signaling pathways are known to interconnect in other cells,[13-15] we performed experiments to determine whether inhibition of Hh by GANT61 might induce Bnip3 expression by way of activation of MEK/ERK. As shown in Fig. 4F, GANT61 treatment increased the phosphorylation of MEK and ERK1/2 (but did not affect the levels of total MEK and ERK1/2). We observed that inhibition of MEK by U0126 prevented GANT61-induced phosphorylation of ERK1/2, expression of Bnip3, and accumulation of LC3II (Fig. 4G). These findings suggest that GANT61-induced Bnip3 expression is mediated at least in part through activation of the MEK/ERK pathway. Although Bnip expression is known to be regulated by nuclear factor kappa B (NF-κB), p53, and DNA methyltransferase-1 (DNMT-1), these molecules were not altered by GANT61 treatment in our system (Supporting Fig. S3).
Bnip3 Mediates GANT61-Induced Beclin-1 Dissociation From Bcl-2
Beclin-1, the mammalian ortholog of yeast Atg6, is a well-known key regulator of autophagy; it is a critical component of the class III phosphatidylinositol-3-kinase complex (PI3KC3) required for autophagy. The overall structure of Beclin-1/Atg6 and its essential role in autophagosome formation is evolutionarily conserved throughout all eukaryotic phyla. Whereas Beclin-1 expression promotes autophagy, Beclin-1 reduction decreases autophagic activity. Sequence alignment and structural modeling indicate that Beclin-1 contains a putative BH3-like domain (amino acids 112-123), which is known as a novel BH-3 domain only protein. The BH-3 domain of Beclin-1 interacts with Bcl-2, which leads to inhibition of autophagy.[21, 22] Given that Bnip3 is a BH3-only protein and that GANT61 significantly up-regulated Bnip3 expression in HCC cells, we speculated that Bnip3 up-regulation by GANT61 might cause Beclin-1 dissociation from Bcl-2. Indeed, as shown in Fig. 5A,B, GANT61 treatment enhanced Bnip3 binding to Bcl-2 and caused Beclin-1 dissociation from Bcl-2. The role of Bnip3 in Beclin-1-Bcl-2 dissociation is further supported by the observations that forced overexpression of Bnip3 augmented GANT61-induced Beclin-1 disassociation from Bcl-2 and that siRNA knockdown of Bnip3 partially reversed GANT61-induced Beclin-1 disassociation from Bcl-2 (Fig. 5C). Consistent with these findings, forced overexpression of Bcl-2 was found to reduce GANT61-induced autophagy in Huh7 cells (Fig. 5D). Taken together, these results indicate that the Gli inhibitor GANT61 up-regulates Bnip3 expression and thus increases Bnip3 association with Bcl-2, which subsequently leads to Beclin-1 dissociation from Bcl-2 and induction of autophagy (illustrated in Fig. 5E).
GANT61-Induced Autophagy Contributes to Induction of Apoptosis
Autophagy is an evolutionarily conserved catabolic process that is thought to promote cell survival in response to stress. However, prolonged or excessive autophagy has also been shown to result in cell death under certain conditions (termed type II programmed cell death).[10, 23] To date, it remains unclear whether autophagy acts fundamentally as a cell survival or cell death pathway, or both. To investigate whether GANT61-induced autophagy might contribute to cell survival or death, we analyzed parameters of cell viability and apoptosis. We observed that GANT61 induced the cleavage of caspase-3, 8, 9, and PARP in Huh-7 cells, as determined by the western blot analysis (Fig. 6A, left panel). Hoechst 33342 staining showed chromatin hypercondensation or fragmentation of nuclei in GANT61-treated Huh7 cells, which are characteristic features of apoptosis (Fig. 6A, right panel). Consistent with these findings, GANT61 treatment decreased cell viability (as determined by WST1 assay) and reduced clonogenic survival capacity (Fig. 6B). On the other hand, treatment with the Hh signaling agonists (SAG or Pur) enhanced cell growth and clonogenic survival capacity (Fig. 6B). Treatment with the autophagic sequestration inhibitor 3-MA attenuated GANT61-induced apoptosis and reduction of cell viability and clonogenic survival capacity (Fig. 6C). The pan-caspase inhibitor zVAD-fmk failed to block GANT61-induced autophagy (Fig. 6D). These observations suggest that GANT61-induced autophagy precede the execution of apoptosis.
Given the role of Bnip3 in GANT61-induced autophagy, we further examined the role of Bnip3 in GANT61-induced apoptosis. As shown in Fig. 6E, knockdown of Bnip3 by siRNA prevented GANT61-induced apoptosis and cytotoxicity. Similarly, siRNA knockdown of Beclin-1 also prevented GANT61-induced apoptosis and cytotoxicity (Fig. 6F). Therefore, GANT61-induced autophagy is not a protective mechanism against apoptosis in HCC cells; rather, it contributes to the induction of apoptosis.
Inhibition of Autophagy by 3-MA and CQ Prevents GANT61-Induced Apoptosis
Apoptosis and autophagy are tightly regulated biological processes and their cross-talk is complex, with conflicting models of interplays (partnership or antagonist) being indicated. To gain insight into variable status between autophagy and apoptosis, we compared the apoptotic effect of GANT61 with other chemotherapeutic agents which have been reported to have cytotoxic effects in HCC cells at indicated concentrations (listed in Supporting Table 1). As shown in Fig. 7A, inhibition of autophagy by 3-MA and CQ partially reversed the cytotoxic effect induced by GANT61, sorafenib (an FDA-approved multikinase inhibitor for treatment of HCC in patients) and other chemotherapeutic/chemopreventive agents in Huh7 cells. However, in HepG2 and Hep3B cells, 3-MA and CQ exhibited variable effects depending on specific chemotherapeutic/chemopreventive agents. Thus, autophagy may contribute to cell survival or death depending on specific context and different cell types. We observed that 3-MA and CQ prevented cytotoxicity induced by GANT61 and sorafenib consistently in all three cell lines. The latter finding is consistent with the data of flow cytometry using Annexin-V/propidium iodide staining showing that inhibition of autophagy by 3-MA and CQ prevented GANT61 and sorafenib-induced apoptosis in Huh7 cells (Fig. 7B). These results are noteworthy, given the role of the Gli inhibitor GANT61 for induction of autophagy and apoptosis in HCC cells as documented in the current study and the fact that sorafenib is the only therapeutic agent currently available for systemic therapy of HCC in patients.
GANT61 Induces Autophagy and Suppresses HCC Growth In Vivo
To assess the antitumor potential of GANT61 and the role of autophagy in vivo, we employed a tumor xenograft model in which Huh7 cells were inoculated into SCID mice and the animals were treated intraperitoneally with vehicle control, GANT61, or GANT61 in combination with 3-MA (intraperitoneal injection, started 1 week after inoculation, performed every other day for 4 weeks). As shown in Fig. 8A,B, GANT61 treatment significantly inhibited Huh7 tumor growth and the effect was attenuated by the autophagy inhibitor 3-MA. Induction of autophagy in GANT61-treated tumor was confirmed by immunofluorescent staining and immunoblotting for LC3II (Fig. 8C,D). GANT61 treatment increased the cleavage of caspase-3 and caspase-8 in tumor tissues and the effect was partially reversed by cotreatment with 3-MA. These results suggest that GANT61-induced autophagy contribute to HCC cell apoptosis and cytotoxicity in vivo and that the activity of autophagy is a key factor that determines the efficacy of Hh-targeted therapy.
This study provides novel evidence that the Hh signaling pathway is a key regulator of autophagy in HCC cells. Although Hh signaling activation in HCC cells may exert an effect on other cell types in the liver (such as hepatic stellate cells, liver progenitor cells, and tumor-initiating stem-like cells), our data provide the first evidence for an autocrine action of Hh signaling in HCC cells. Our data show that inhibition of Gli by GANT61 induces autophagy, whereas activation of Hh signaling by its ligand and agonists inhibits autophagic activity. This process is mediated by Bnip3, which displaces Bcl-2 from Beclin-1. Moreover, our data show that inhibition of autophagy attenuates GANT61-induced apoptosis. These findings provide the first evidence that Hh signaling regulates autophagy and that autophagic activity is a key factor that determines cell response to Hh-targeted therapy.
We have found that GANT61-induced autophagy is mediated through up-regulation of Bnip3, which displaces Bcl-2 from Beclin-1. The Bcl-2 family of proteins is an important regulator of both apoptosis and autophagy and contains both anti- and proapoptotic members. The antiapoptotic members (e.g., Bcl-2, Bcl-xL, and Mcl-1) protect cells from apoptosis and contain characteristic regions of Bcl-2 homology (BH) domains (BH1, BH2, BH3, and BH4). The proapoptotic members of the family are divided into two subgroups: proteins that contain two or three BH domains; and proteins that contain only BH3, the domain essential for binding to the antiapoptotic members of the family (so-called BH3-only proteins). The BH3-only proteins (such as Noxa, Bad, Bnip3, and Puma) act as sentinels of stress or damage and are key instigators of cell death in many situations; they are also known to induce autophagy. Beclin-1, a key player in the initiation of autophagy, was recently identified as a new member of the BH3-only proteins (the BH3 domain of Beclin-1 interacts with Bcl-2 and this interaction leads to suppression of autophagy).[21, 22] In this study, we found that inhibition of Gli by GANT61 significantly increased the protein and mRNA levels of Bnip3 in all three HCC cell lines and that Bnip3 induced dissociation of the Beclin-1/Bcl-2 binding complex. Our findings suggest a model in which inhibition of Hh signaling causes up-regulation of Bnip3 and this leads to dissociation of the Beclin-1/Bcl-2 binding complex and subsequent induction of autophagy. In spite of the robust up-regulation of Bnip3 by GANT61 in all three HCC cell lines, the expression of other Bcl-2 family proteins was not significantly affected, except for Mcl-1. In our system, the level of Mcl-1 was slightly reduced by GANT61 treatment in two of the three HCC cell lines. It remains to be determined whether Mcl-1 reduction might also contribute to GANT-induced HCC cell apoptosis, although it is beyond the scope of the current study. Further investigations are warranted to dissect the emerging connections between Hh signaling and the Bcl-2 family proteins.
Several molecules have been implicated in the modulation of Bnip3 expression, including MEK/ERK,[11, 12] NF-κB, p53, and methylation of Bnip3 promoter by DNA-methyltransferase 1. In the current study, we observed that GANT61 treatment activated the MEK/ERK signaling, as reflected by increased phospho-MEK and phospho-ERK1/2. The MEK inhibitor U0126 prevented GANT61-induced up-regulation of Bnip3 expression and LC3 accumulation. These observations suggest that Hh inhibition by GANT61 up-regulates the expression of Bnip3, at least in part, through activation of the MEK/ERK signaling pathway. As activation or inhibition of the Hh signaling pathway did not affect the levels of NF-κB, p53 and DNMT1/DNMT3a, these molecules do not appear to be involved in GANT61-induced up-regulation of Bnip3 in HCC cells.
The role of autophagy in caner development and progression is complex. Whereas deficiency of autophagy can predispose to the initiation of tumor development, excessive or prolonged activation of autophagy may promote cancer cell death. Paradoxically, autophagy is also known to enhance cancer cell survival in response to some environmental and cellular stresses (e.g., nutrient deprivation, organelle damage, hypoxia, or therapeutic stress) and causes resistance to antineoplastic therapies. In this study we attempted to explore whether autophagy induced by GANT61 in HCC cells is a cell death or survival mechanism. We provided in vitro and in vivo evidence that inhibition of Gli by GANT61 induces both autophagy and apoptosis in HCC cells and that blockage of autophagy reverses GANT61-induced apoptosis and cytotoxicity. Although the role of autophagy in cell survival and death may depend on specific agents and cell types, our data clearly demonstrate that autophagy contributes to HCC cell apoptosis induced by the Gli inhibitor GANT61, a promising new anticancer drug, and by the multikinase inhibitor sorafenib, the only FDA-approved drug for target therapy of HCC.
Inhibition of Hh signaling has been attempted in various human cancer models. Several natural and synthetic pharmacologic agents for modulation of Hh activity have been identified and developed. Historically, Smo antagonists including cyclopamine and GDC-0449 have been used to abrogate Hh signaling in human cancers, with moderate success. A potentially more potent target lies in the family of Gli transcription factors, which are the final arbiters of transcriptional regulation in the Hh signaling pathway. GANT61 is a recently identified small molecule inhibitor of Gli, which has been shown to effectively block Gli-1 and Gli-2 activities and induce more significant cytotoxicity in human cancer cells than Smo antagonists. In HCC cells, we observed that the Gli inhibitor GANT61 induced more prominent autophagy and apoptotic cell death compared to the Smo inhibitor GDC-0449.
In conclusion, this study shows that the Hh signaling pathway importantly regulates autophagy and that inhibition of Hh signaling activates autophagy in human HCC cells at least in part through induction of Bnip3, which prevents Beclin-1 binding to Bcl-2. Furthermore, we show that autophagy contributes to GANT61-induced apoptosis and inhibition of growth in HCC cells. These findings provide the first evidence that Hh signaling regulates autophagy and that autophagic activity is a key factor that determines cell response to Hh-targeted therapy.
The authors thank the Louisiana Cancer Research Consortium FACS Core facility for flow cytometry analysis.